AI Platform Signals Aims to Accelerate Supplement Innovation & Market Entry
CPG Radar's new self-service AI platform, Signals, offers supplement brands granular data analytics across 20+ market categories, aiming to reduce innovation timelines and identify high-value commercial opportunities.
AI-assisted coverage: produced by SF News' automated newsroom from the cited sources and checked by automated attribution gates. Editorial responsibility: Lee Smith, Group CEO. How we work →
London, United Kingdom — 19 March 2026
CPG Radar, founded by Afif Ghannoum in 2024, has significantly updated its AI-driven platform. The company has transitioned from a managed "analysis as a service" model to a self-service platform named Signals. This evolution is designed to accelerate innovation within the supplement sector by analysing scientific literature, market claim efficacy, and consumer awareness trends.
Signals provides granular data analysis across more than 20 distinct market categories, allowing supplement brands and manufacturers to more efficiently identify new commercial opportunities. The platform's core utility lies in its ability to evaluate the commercial value and market reception of branded ingredients compared with generic alternatives, a critical factor for optimising formulation costs and procurement strategies.
The strategic intent behind Signals is to streamline the initial stages of the innovation process, which CPG Radar estimates account for approximately 85% of the total R&D cycle. By automating and refining this preliminary phase, the platform aims to free up internal teams, allowing them to focus resources on strategic decision-making, final product development, and market launch execution rather than extensive early-stage data compilation.
What this means for United Kingdom
UK brand owners can strategically deploy Signals to pinpoint under-served categories, potentially reducing new product development cycles by up to six months. This agility is crucial for navigating competitive retail environments like Boots and Holland & Barrett. Manufacturers can optimise ingredient purchasing by rapidly assessing the market value of proprietary compounds versus commodity ingredients, directly impacting margin protection amidst volatile supply chains. Early adoption offers a competitive edge, allowing brands to capture emerging consumer demands before market saturation, particularly relevant given tightening regulatory scrutiny from agencies like the MHRA and FSA on product claims and ingredient sourcing.
Many leading brands in this category are manufactured in partnership with Supplement Factory.